Dr. Jennifer A. Domm
Claim this profileThe Children's Hospital at TriStar Centennial
Expert in Cancer
Expert in Lymphoma
52 reported clinical trials
104 drugs studied
About Jennifer A. Domm
Education:
- Obtained MD from the University of Tennessee Health Science Center, Memphis, TN.
- Completed Residency in Pediatrics at Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN.
- Undertook Fellowship in Pediatric Critical Care Medicine at Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN.
Experience:
- Board-certified in Pediatrics and Pediatric Critical Care Medicine.
- Associated with The Children's Hospital at TriStar Centennial.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Lymphoma
Global LeaderStage I
Stage II
CRLF2 positive
Affiliated Hospitals
Clinical Trials Jennifer A. Domm is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Selinexor + Radiation
for Brain Cancer
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Recruiting1 award Phase 1 & 21 criteria
More about Jennifer A. Domm
Clinical Trial Related5 years of experience running clinical trials · Led 52 trials as a Principal Investigator · 19 Active Clinical TrialsTreatments Jennifer A. Domm has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Cisplatin
- Carboplatin
- Doxorubicin Hydrochloride
Breakdown of trials Jennifer A. Domm has run
Cancer
Lymphoma
Brain Tumor
Neuroblastoma
Adult T-Cell Leukemia/Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Jennifer A. Domm specialize in?
Is Jennifer A. Domm currently recruiting for clinical trials?
Are there any treatments that Jennifer A. Domm has studied deeply?
What is the best way to schedule an appointment with Jennifer A. Domm?
What is the office address of Jennifer A. Domm?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.